National Bank announces acquisition and intended cancellation plan for own shares

Pavlos Mylonas CEO
Pavlos Mylonas CEO
0Comments

National Bank of Greece S.A. has announced the completion of a series of transactions involving the purchase of its own shares. This follows resolutions from the Annual General Meeting on May 30, 2025, and subsequent announcements in June and July 2025.

Between July 3 and July 10, 2025, the bank acquired a total of 419,910 common shares on the Athens Stock Exchange. The weighted average price per share was €11.3403, resulting in a total expenditure of €4,761,913.12.

The breakdown of these transactions is as follows: On July 3rd, 109,910 shares were purchased at an average price of €11.1542 each; on July 4th, another batch of 30,000 shares was bought at €11.1063 each; on July 7th, an additional purchase included 100,000 shares at €11.0843 each; on July 8th, there were purchases totaling 60,000 shares at €11.3549 each; followed by another set of purchases on July 9th with the same number of shares at €11.6233 each; finally concluding with a purchase on July 10th for another set of 60,000 shares priced at €11.9274 each.

Following these acquisitions, National Bank holds directly a total of approximately five million one hundred twenty-three thousand one hundred fifty-four Own Shares corresponding to about half a percent (0.56%) stake within its entire share capital framework.

The announcement aligns itself under provisions stated by EU Regulation No596/2014 alongside Commission Delegated Regulation (EU)2016/1052 plus Resolution No25 enacted via Stock Markets Steering Committee associated with Athens Exchange ensuring transparency regarding this corporate activity.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.